What the Study Found (In Plain English)
Published in Pharmaceutical research (2006), this randomized controlled trial evaluating 614 human participants investigated: To develop a model to explore the dose-response of sildenafil citrate in patients with female sexual arousal disorder (FSAD) based on telephone sexual activity daily diary (TSADD) data obtained in double-blind, placebo controlled clinical studies. Key clinical takeaway: A modeling and simulation framework to support drug development in FSAD was developed. Sildenafil citrate demonstrated a dose-dependent effect in patients with FSAD.
Dr. Lin (AI Evidence Lead): Statistical Endpoints & Numbers
Primary Endpoint & Quantitative Summary (Pharmaceutical research, 2006-08-15; N = 614; Rigor 93/100): A modeling and simulation framework to support drug development in FSAD was developed. Sildenafil citrate demonstrated a dose-dependent effect in patients with FSAD.
Study Limitations & Caveats Before You Act
Clinical trials evaluate specific inclusion/exclusion cohorts under protocol-controlled conditions (Randomized Controlled Trial). Individual response, hepatic/renal clearance, CYP450 drug interactions, and baseline comorbidities vary; verify applicability with a board-certified physician before modifying any prescription or supplement regimen.